CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 444 filers reported holding CRISPR THERAPEUTICS AG in Q1 2021. The put-call ratio across all filers is 1.14 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $312,397 | -20.6% | 6,883 | -1.8% | 0.08% | -21.1% |
Q2 2023 | $393,401 | +26.0% | 7,008 | -0.9% | 0.10% | +15.9% |
Q1 2023 | $312,211 | +7.1% | 7,070 | -1.4% | 0.08% | +6.5% |
Q4 2022 | $291,461 | -39.5% | 7,170 | -2.7% | 0.08% | -46.2% |
Q3 2022 | $482,000 | -12.8% | 7,370 | 0.0% | 0.14% | +1.4% |
Q2 2022 | $553,000 | +52.8% | 7,370 | +27.7% | 0.14% | +62.1% |
Q1 2022 | $362,000 | -9.5% | 5,770 | +9.4% | 0.09% | -23.7% |
Q4 2021 | $400,000 | -9.9% | 5,272 | +32.8% | 0.11% | -21.4% |
Q3 2021 | $444,000 | -31.4% | 3,971 | -0.7% | 0.14% | -32.9% |
Q2 2021 | $647,000 | +32.9% | 3,999 | 0.0% | 0.22% | +16.1% |
Q1 2021 | $487,000 | +23.9% | 3,999 | +55.6% | 0.19% | -11.0% |
Q4 2020 | $393,000 | +24.0% | 2,570 | -32.3% | 0.21% | +6.1% |
Q3 2020 | $317,000 | +41.5% | 3,795 | +24.4% | 0.20% | +21.6% |
Q2 2020 | $224,000 | -3.0% | 3,050 | -22.8% | 0.16% | +8.0% |
Q4 2019 | $231,000 | +13.8% | 3,950 | -20.2% | 0.15% | +8.7% |
Q3 2019 | $203,000 | -12.9% | 4,950 | 0.0% | 0.14% | -8.0% |
Q2 2019 | $233,000 | +13.1% | 4,950 | -16.1% | 0.15% | +10.3% |
Q1 2019 | $206,000 | – | 5,900 | – | 0.14% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |